By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Relmada Therapeutics 



  New York    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS








Company News
Relmada Therapeutics Release: Announces FDA Acceptance Of IND And Authorization To Commence Phase 2a Clinical Trial For D-Methadone 1/26/2017 7:38:38 AM
Relmada Therapeutics Release: Pharma To Provide An Update On The Development Plan For LevoCap ER 1/25/2017 11:54:48 AM
Relmada Therapeutics Announces Issuance Of Key U.S. Patent Covering D-Methadone, An NMDA Receptor Antagonist, For The Treatment Of Depression And Other Psychiatric Symptoms 10/20/2016 9:56:24 AM
Relmada Therapeutics Announces Issuance Of Key U.S. Patent Covering D-Methadone, An NMDA Receptor Antagonist, For The Treatment Of Depression And Other Psychiatric Symptoms 10/19/2016 6:56:33 AM
Relmada Therapeutics To Present At The 15th Annual BIO Investor Forum 10/6/2016 9:30:42 AM
Relmada Therapeutics' Chief Scientific Officer Dr. Richard Mangano To Speak About D-Methadone As A Potential Rapid Acting Antidepressant At Neuro Advance Boston 9/28/2016 7:42:10 AM
Relmada Therapeutics To Present At The Ladenburg Thalmann 2016 Healthcare Conference 9/22/2016 10:30:03 AM
Relmada Therapeutics To Present At The 2016 Aegis Growth Conference 9/20/2016 11:21:56 AM
Relmada Therapeutics Files Amended Complaint Against Laidlaw And Its Principals, Matthew Eitner And James Ahern 9/14/2016 10:13:04 AM
Pharmaceutical Industry Leader Ronald M. Burch Joins Relmada Therapeutics Advisory Team 9/12/2016 6:54:11 AM
12345678910
//-->